Advertisement
Organisation › Details
Recordati S.A. (CH)
Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 3,200, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Central and Eastern Europe, and in Turkey. A field force of around 1,700 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses from companies which do not have a European presence. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2011 was € 762.0 million, operating income was € 163.5 million and net income was € 116.4 million. *
Start | 2012-08-04 existent | |
Group | Recordati (Group) | |
Industry | pharmaceutical | |
Region | Switzerland_oo | |
Country | Switzerland | |
Street | 4 Piazza Boffalora | |
City | 6830 Chiasso | |
Tel | +41-91-682-6008 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Recordati (Group)
- [1] Recordati Industria Chimica e Farmaceutica S.p.A.. (12/3/21). "Press Release: Recordati to Acquire EUSA Pharma (UK) Ltd., a Global Specialty Pharmaceutical Company Focused on Rare and Niche Oncology Diseases". Milan....
- [2] Iqvia. (4/30/18). "Press Release: Recordati Selects Iqvia’s OCE Technology Platform and OneKey Information Services". Danbury, CT & Research Triangle Park, NC....
- [3] Erytech Pharma. (12/8/17). "Press Release: Erytech Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML". Lyon....
- [4] AstraZeneca plc. (5/22/17). "Press Release: AstraZeneca Enters Agreement with Recordati for Seloken in Europe"....
- [5] Recordati Industria Chimica e Farmaceutica S.p.A.. (1/27/17). "Press Release: Recordati Announces Marketing Approval for Cystadrops". Milan....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top